Our Pipeline
Our work using machine learning for bacteria, viruses, parasites and rare diseases has demonstrated that we can identify molecules with potential in vivo activity that can lead to NIH funding to build our pipeline of drug candidates.
Dr. Ekins provides highlights on Ebola, COVID-19, Alzheimer’s, Pitt Hopkins and other assets.
Machine learning and in vitro assays led to recent laboratory results: finding molecules for GSK3β and AChE targets.